Cost and value in liver disease guidelines: 2011-2022

Chronic liver disease (CLD) is associated with rising health care utilization and cost. We aimed to describe the frequency of cost/value (C/V) statements in CLD-related clinical guidance documents (CGDs). CGD with a focus on CLD published between January 2011 and February 2022 from 3 US societies [A...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology communications 2023-01, Vol.7 (1), p.e0001-e0001
Main Authors: Aby, Elizabeth S, Kaplan, Alyson, Ufere, Nneka N
Format: Article
Language:English
Subjects:
Delivery of Health Care
Humans
Liver Diseases - therapy
Original
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic liver disease (CLD) is associated with rising health care utilization and cost. We aimed to describe the frequency of cost/value (C/V) statements in CLD-related clinical guidance documents (CGDs). CGD with a focus on CLD published between January 2011 and February 2022 from 3 US societies [Association for the Study of Liver Diseases (AASLD), American College of Gastroenterology (ACG), and American Gastroenterological Association (AGA)] were analyzed. Forty-five CGDs were identified. Eighty of 1334 guidance statements were C/V statements (6%). Only 1.1% reported patient-level costs and none reported out-of-pocket costs. Despite the increased importance of incorporating cost and value into care, the proportion of C/V statements in CGDs related to liver disease is low.
ISSN:2471-254X
2471-254X
DOI:10.1097/HC9.0000000000000001